Join
Live feed
·
PRReleasevia Quantisnow
Gilead Sciences Inc. logo

U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

ByQuantisnow·Wall Street's wire, on your screen.
GILD· Gilead Sciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GILD (Gilead Sciences Inc.) and more on Quantisnow.